Clinical Research Directory

Inclusion Criteria: * Women diagnosed with breast cancer * Being of legal age * Histologically confirmed primary Breast Cancer (I-IIIA) (without the presence of metastasis) with a diagnosis in the last year * Unilateral involvement * Surgery for the tumor at least 6 weeks before the start of the intervention * WHO performance status of 0 (asymptomatic, complete and ambulatory activity) * Correct understanding of Spanish * Approval by signing the informed consent; * Mus be considered at risk for developing LACM: 1) Have undergone surgery that includes axillary dissection; 2) Have received or are undergoing regional lymph node radiation; 3) BMI \>30 kg/m2. . These patients are considered to have stage 0, subclinical or latent according to the International Society of Lymphology (ISL) , since they will not present signs or symptoms, but lymphatic transport will be altered by the treatments themselves Exclusion Criteria: * Women already diagnosed with LACM in stage I, II or III according to the ISL or if they present an L-Dex ratio \> 10 or a difference in volume equal to or greater than 10% between both extremities * Suffer from or have been diagnosed with any other lymphatic-venous disease in the upper extremity, such as venous insufficiency, thrombosis or lipedema; * Suffer from conditions that prevent resistance exercise of the upper body * Participation in regular (\>1 time/week) and intense exercises involving the upper extremity during the last month * Suffer from heart disease * Inability to complete questionnaires; * A physical condition that prevents them from making hospital visits * Taking any drug that may affect the lymphatic and circulatory system, such as diuretics or corticosteroids * Women which presents some type of wound or infection on the skin.